Updating results

2 results

Sort: Relevance | Date

Pembrolizumab with axitinib for untreated advanced renal cell carcinoma [ID1426]: appraisal consultation

We are listening to your views on this technology appraisal guidance. Comments close 04 March 2020.

Technology appraisal guidance In consultation

Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]: appraisal consultation

We are listening to your views on this technology appraisal guidance. Comments close 21 February 2020.

Technology appraisal guidance In consultation